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A phenotype of Escherichia coli and Klebsiella pneumoniae, resistant to piperacillin/tazobactam
(TZP) but susceptible to carbapenems and 3rd generation cephalosporins, has emerged. The
resistance mechanism associated with this phenotype has been identified as hyperproduction
of the β-lactamase TEM. However, the mechanism of hyperproduction due to gene ampli-
fication is not well understood. Here, we report a mechanism of gene amplification due to a
translocatable unit (TU) excising from an IS26-flanked pseudo-compound transposon,
PTn6762, which harbours blaTEM-1B. The TU re-inserts into the chromosome adjacent to IS26
and forms a tandem array of TUs, which increases the copy number of blaTEM-1B, leading to
TEM-1B hyperproduction and TZP resistance. Despite a significant increase in blaTEM-1B copy
number, the TZP-resistant isolate does not incur a fitness cost compared to the TZP-
susceptible ancestor. This mechanism of amplification of blaTEM-1B is an important con-
sideration when using genomic data to predict susceptibility to TZP.
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β-lactam/β-lactamase inhibitor combinations were developedto overcome the activity of β-lactamases1,2, which inactivateβ-lactam antibiotics by hydrolysing the β-lactam ring. β-
lactamase inhibitors, particularly metallo-β-lactamase inhibitors, are
still urgently required and their discovery and development is the
topic of intense investigation3. β-lactam/β-lactamase inhibitor
combinations currently in clinical use include amoxicillin/clavulanic
acid, ampicillin/sulbactam and piperacillin/tazobactam (TZP), with
ceftolozane/tazobactam and ceftazidime/avibactam recently intro-
duced into clinical use. TZP has broad-spectrum antibacterial
activity and is routinely used for intra-abdominal infections and
febrile neutropenia4,5. TZP usage has increased year on year in the
UK, from just under 2.1% of all antibiotics prescribed in 2008–2009
to 3.6% in 2012–20136. During the 2-year period between April
2012 and March 2014 10.2% of bacteraemia causing Escherichia coli
isolates in England tested for TZP susceptibility were resistant7.
Resistance to TZP has been previously linked to AmpC hyper-
production and the co-production of multiple β-lactamases, which
also confer resistance to 3rd generation cephalosporins8. In addi-
tion, tazobactam is a poor inhibitor of metallo-β-lactamase
enzymes, which cause resistance to TZP, alongside 3rd generation
cephalosporins and carbapenems9–11.
A phenotype in Klebsiella pneumoniae and E. coli clinical isolates
has emerged which has been classified as TZP-non-susceptible but
susceptible to 3rd generation cephalosporins and carbapenems12–14,
indicating a different resistance mechanism. While still relatively
rare, one study in the United States found that the frequency of this
phenotype was between 1.9 and 5.6% of E. coli and K. pneumoniae
isolated from the bloodstream between 2011 and 2015, and speci-
fically 4.1% of all E. coli over the study period14. The same study
reported that risk factors associated with the TZP-non-susceptible
but 3rd generation cephalosporin and carbapenem susceptible
phenotype included exposure to β-lactam/β-lactamase inhibitors
and cephalosporins within the previous 30 days14. Resistance to
TZP, but 3rd generation cephalosporin and carbapenem suscep-
tible, has been linked to the presence of β-lactamases which
hydrolyse piperacillin but not 3rd generation cephalosporins. The
β-lactamases such as SHV-1 and TEM-1 are usually inhibited by
tazobactam, which also has an intermediate inhibitory activity
towards OXA-115,16. TEM has been hypothesised to overcome the
inhibitory activity of tazobactam via hyperproduction of the
enzyme, allowing the hydrolysis of piperacillin17. Mechanisms
leading to hyperproduction include mutations in the promoter
region of blaTEM, changing it from a weak promoter (P3) to a
stronger promoter (P4 or P5)18 or a single point mutation further
upstream resulting in the overlapping, stronger promoter Pa/Pb
superseding the weaker P3 promoter19, increasing the production of
TEM. Another such mechanism proposed to cause TZP-resistance
but 3rd generation cephalosporin and carbapenem susceptibility is
the increase in copy number of blaTEM present in either a plasmid
or chromosome17,20. Gene amplification has been linked to the
cause of temporary antibiotic resistance seen in a sub-population of
bacteria and is known as heteroresistance. Heteroresistance is often
lost after multiple generations in the absence of antibiotic selective
pressure, due to the fitness cost imposed by the production of extra
proteins as a result of amplification21,22. While the mechanism of
amplification of blaTEM is not well known, recent studies have
found that the amplified blaTEM has been co-located on a segment
of DNA containing other antibiotic resistance genes, such as aadA
and sulI, termed a genomic resistance module17. Amplification of
blaTEM leading to TZP resistance via β-lactamase hyperproduction
has also been suggested to be mediated by the presence of the
insertion sequence, IS2620. IS26 is often linked with the movement
of antibiotic resistance genes; for example a translocatable unit (TU)
containing IS26 has been shown to be able to excise from the
transposon Tn4352B, which itself was located on a plasmid,
between two IS26, leaving one in the plasmid23,24. Recently, directly
repeated IS26 elements, plus the interveining DNA, have been
labelled as pseudo-compound transposons (PTns)25 rather than
composite transposons as they do not transpose as an entire
unit. Following excision, the single IS26 and antibiotic resistance
gene(s) found between the two insertion sequences forms a circular
TU, which then can insert into a plasmid via a conservative Tnp26-
dependent but RecA-independent mechanism, Tnp26 replicative
transposition or RecA-dependent homologous recombination,
preferentially adjacent to another IS26 insertion sequence23,24,26.
Here, we identify a pair of clonal E. coli isolates, isolated from a
single patient across two separate infection episodes, which display
within-patient evolution to TZP resistance. In this isolate, ampli-
fication of blaTEM-1B occurs when a TU excises from a pseudo-
compound transposon flanked by directly repeated IS26 present in
the chromosome. The TU re-inserts into the chromosome creating
a tandem array of the TU and increasing the copy number of
blaTEM-1B, which does not carry a fitness cost. Replicating the
evolutionary event in vitro in the TZP-susceptible isolate leads to
the capture of the TU in a plasmid which contains a copy of IS26.
Results
Identification of clonal isolates. Initially, we identified five isolates
in the collection of TZP-resistant, 3rd generation cephalosporin and
carbapenem susceptible E. coli from blood cultures at the Royal
Liverpool University Hospital (RLUH) which had a corresponding
TZP-susceptible isolate from the same or previous infection epi-
sode, and therefore could have evolved to become TZP-resistant
within a patient. Restriction fragment length polymorphisms
(RFLP) of the 16S rRNA amplicons from the five pairs of isolates
indicated that three pairs of TZP-susceptible/TZP-resistant clinical
isolates had identical digestion patterns (Supplementary Fig. 1A).
Two of these three pairs of isolates had an identical resistance
profile generated during routine disk-based susceptibility testing,
aside from TZP (Supplementary Table 1). RFLPs of genomic DNA
identified one pair of isolates with identical banding patterns
indicating clonality; 190693 (TZP-susceptible) and 169757 (TZP-
resistant) which were isolated from different infection episodes
from the same patient ~3 months apart (Supplementary Fig. 1B).
During the first infection episode, the TZP-susceptible E. coli was
isolated and the patient was initially treated with a five-day course
of TZP, followed by a seven-day course of TZP with teicoplanin and
then a third seven-day course of TZP although a second blood
culture was found to be negative. A second infection episode
occurred ~6–7 weeks after the final course of TZP was completed,
and again the patient was treated initially with TZP until the TZP-
resistant E. coli was isolated, when the treatment was changed to
meropenem. Putative clonality of these two isolates was confirmed
with whole-genome sequencing; both isolates were identified as
serotype H30 O86, sequence type 315 and had an average
nucleotide identify (ANI) of 100%, with 36 single nucleotide
polymorphisms (SNP) difference between the two isolates.
Confirmation of TZP susceptibility and resistance mechanism.
We determined the minimum inhibitory concentrations (MIC) of
the pair of isolates and verified that TZP-susceptible isolate was
susceptible to TZP (2–4/4 µg/ml) and TZP-resistant isolate was
resistant to TZP (64/4 µg/ml) according to European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical break-
points27 (Table 1). Using the efflux pump inhibitor phenylalanine-
arginine β-naphthylamide (PAβN) as a supplement in the MIC
assay, we were able to rule out overexpression of efflux pumps as a
possible mechanism of resistance as there was less than a fourfold
reduction17 in MIC of both the TZP-susceptible (2/4 µg/ml)
and TZP-resistant isolates (32/4 µg/ml, Table 1). Whole-genome
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sequencing revealed no differences in the predicted resistance genes
present in the genome between the TZP-susceptible and TZP-
resistant isolate (Table 2) and no mutations in the promoter region
of any of the β-lactamases present within the genome (blaTEM-1B,
blaOXA-1 or ampC) of the TZP-resistant isolate. We confirmed that
the TZP-resistant isolate hyperproduced a β-lactamase due to the
significant increase in nitrocefin hydrolysis compared to the TZP-
susceptible isolate (P value= <0.0001, Fig. 1a, Supplementary
Table 3). The isolates contained two β-lactamases, TEM-1B and
OXA-1, which were both increased in copy number in the TZP-
resistant isolate compared to the housekeeping gene uidA (Fig. 1b).
We, therefore determined whether TEM-1B, OXA-1 or both
contributed to TZP resistance using increased amount of tazo-
bactam to inhibit TEM-1B and 100mM sodium chloride to inhibit
OXA-128–30. Increasing tazobactam from 4 to 8 µg/ml and 4 to 16
µg/ml resulted in a twofold and eightfold decrease in TZP MIC
respectively, while supplementation of 100mM sodium chloride
decreased the TZP MIC by twofold (Supplementary Table 2). As
there was only a modest decrease in resistance in the presence of
sodium chloride, it is likely hyperproduction of TEM-1B is the most
important determinant of resistance to TZP.
Genomic comparison of the clonal isolates. Using a hybrid
assembly of Oxford Nanopore Technologies (ONT) long and Illu-
mina short sequencing reads, we were able to complete the genome
of the TZP-susceptible isolate, which was found to be 5151952 bp in
length, with a GC content of 50.64% and did not contain any
plasmids (Supplementary Fig. 2A). In contrast, we were unable to
complete the genome of the TZP-resistant isolate as a 530 bp seg-
ment remained unresolved, and a complete, low copy number
(2.59x) 106637 bp plasmid containing an IncFII replicon (Supple-
mentary Fig. 2B) was detected. A complete, smaller (10899 bp)
circular DNA molecule was also found to be present in the
TZP-resistant isolate, at a copy number of 8.51x, however, this small
circular DNA molecule did not contain a plasmid replicon (Sup-
plementary Fig. 2B). The large plasmid did not to contain any
predicted antimicrobial or metal resistance genes, but did contain
three bacteriocins, both colicin B and M (with cognate immunity
proteins) and linocin. Comparison of the predicted resistance genes
present on the chromosome of the TZP-susceptible and TZP-
resistant isolates highlighted that blaTEM-1B, blaOXA-1, aac(3)-lla, aac
(6’)-lb-cr, tet(D) and catB3 were missing from the assembled
chromosome of the TZP-resistant isolate (Table 2). Characterisation
of the small circular DNA molecule found that it contained these
missing resistance genes, as well as several putative transposable
elements including three copies of IS26 (Table 2), and aligned
exactly to the chromosome of the TZP-susceptible isolate and was
no longer present in the chromosome of the TZP-resistant isolate.
The predicted catB3 resistant gene was truncated to 69.8% length
and therefore unlikely to be functional, which was confirmed as
both the TZP-susceptible and TZP-resistant isolates were suscep-
tible to chloramphenicol (CHL) according to EUCAST clinical
breakpoints (Table 1). Further analysis of the TZP-susceptible
genome uncovered that the circular DNA molecule from the TZP-
resistant isolate aligned with 100% identity to an integrated pseudo-
compound transposon flanked by two copies of IS26 in the same
orientation, which we subsequently registered as PTn6762 via The
Transposon Registry31, however, the circular DNA molecule only
contained one of the flanking IS26. The antibiotic resistance genes
blaTEM-1B, blaOXA-1, aac(3)-lla, aac(6’)-lb-cr and tet(D) were iden-
tified to be present on PTn6762 (Fig. 2a). This suggested that a
TU23,24,26, containing one flanking IS26 and the antibiotic resis-
tance genes, was excised from the chromosomally located PTn6762
while the other flanking IS26 stayed in the chromosome (Fig. 2a).
Interestingly, we also found that the tetracycline resistance reg-
ulator, tetR, on the TU had been disrupted 52 bp from the end of
the tetR due to the excision which overlaps the start of the copy of
IS26 remaining in the chromosome. Following excision, a copy of
IS26 is present at the start of the TU which then connects to the end
of the TU, containing the disrupted tetR, forming a circular DNA
molecule. As the two copies of IS26 are identical and in the same
orientation, and therefore containing the same 52 bp bases missing
from tetR, tetR was reformed when the TU circularised completing
the 657 bp gene.
Confirmation of the amplification of the TU. Firstly, we con-
firmed the amplification of the resistance genes found on the TU
in the TZP-resistant isolate and PTn6762 in the chromosome of
the TZP-susceptible isolate. Comparing the fold change in copy
number of each resistant gene to the housekeeping gene uidA, we
found that each resistance gene on the TU increased in copy
number in the TZP-resistant isolate compared to the TZP-
susceptible isolate (P value= <0.0001, Fig. 1b, Supplementary
Table 3). The increase in copy number of the resistance genes
found on the TU in the TZP-resistant isolate also corresponded to
an increase in MIC of all antimicrobials that the genes confer
resistance to (Table 1), further confirming the amplification of the
Table 1 Minimum inhibitory concentrations of the piperacillin/tazobactam-resistant and piperacillin/tazobactam-susceptible
isolates.
GEN TET CHL CIP AMC TZP TZP+ PAβN
TZP-susceptible 128 µg/ml 256 µg/ml 4 µg/ml 64 µg/ml 32 µg/ml 2–4/4 µg/ml 2/4 µg/ml
TZP-resistant 1024–>1024 µg/ml 512 µg/ml 4 µg/ml 128 µg/ml 64–128 µg/ml 64/4 µg/ml 32/4 µg/ml
Minimum inhibitory concentrations (MIC) of gentamicin (GEN), tetracycline (TET), chloramphenicol (CHL), ciprofloxacin (CIP), amoxicillin/clavulanic acid (AMC) and piperacillin/tazobactam (TZP)
(with and without Phenylalanine-arginine β-naphthylamide (PAβN)) towards the TZP-susceptible and TZP-resistant isolates. Determination of MICs were performed in triplicate (n= 3).
Table 2 Predicted antimicrobial resistance genes.
Antimicrobial
resistance gene
TZP-susceptible
isolate
TZP-resistant isolate
blaOXA-1 Chromosome Translocatable unit
blaTEM-1B Chromosome Translocatable unit
aac(3)-lla Chromosome Translocatable unit
aac(6’)-lb-cr Chromosome Translocatable unit
aadA1 Chromosome Chromosome
aph(3”)-lb Chromosome Chromosome
aph(6)-ld Chromosome Chromosome
tet(D) Chromosome Translocatable unit
dfrA1 Chromosome Chromosome
sul2 Chromosome Chromosome
mdf(A) Chromosome Chromosome
catB3 Chromosome Translocatable unit
Predicted antimicrobial resistance genes by ResFinder found on the genome of the piperacillin/
tazobactam (TZP)-susceptible and TZP-resistant isolates and their position in genome. The
resistance gene catB3 was predicted by ResFinder to be present with 69.8% length, but both
isolates were phenotypically chloramphenicol susceptible.
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entire TU. By PCR of the left and right junctions of the chro-
mosomally located PTn6762, with one primer specific for
PTn6762 and one for the chromosome either before or after IS26
(Fig. 2b, Supplementary Table 4), we were able to confirm that
PTn6762 was present in the chromosome of both the TZP-
susceptible isolate and TZP-resistant isolate by yielding the
expected 1640 bp and 2402 bp products, respectively (Supple-
mentary Fig. 3). Using primers that would only yield a 1942 bp
product if a tandem TU array in the chromosome was present
(Fig. 2c), we were able to detect the presence of the tandem TU in
the TZP-resistant isolate and absence in the TZP-susceptible
isolate (Supplementary Fig. 3). To further confirm that the TU is
present in the chromosome in tandem arrays, we mapped the
long-read sequences to a predicted structure of three tandem TUs
and built a consensus sequence out of these reads. We were
unable to build a consensus sequence for the TZP-susceptible
isolate, suggesting the TU was not present in the chromosome in
a tandem array. In contrast, we were able to build a consensus
sequence for the TZP-resistant isolate, which showed 99.89%
identity to the predicted sequence (Supplementary Fig. 4). This
suggests that the TU from PTn6762 has excised and reinserted to
form a tandem array within the chromosome of the TZP-resistant
isolate.
Capture of the TU. We sought to capture the excised TU, and
therefore observe the excision and insertion events, using a CHL
resistant, high copy number pUC plasmid (pHSG396) containing
IS26 in the same orientation relative to the origin of replication as
found on PTn6762 (Supplementary Methods 1). pHSG396:IS26 was
transformed into the TZP-susceptible isolate and TZP-resistant
derivatives were selected for by growing the isolate in the presence
of TZP. We detected the insertion of a >10 kb fragment into
pHSG396:IS26 after TZP selection following digestion with XhoI
and EcoRI (Supplementary Fig. 5A). Insertion of the TU from the
TZP-susceptible chromosome was confirmed through PCR ampli-
fication across the two newly formed junctions on the pHSG396:
IS26, with one primer specific for pHSG396 and one for either aac
(6’)-lb-cr (left) or tet(D) (right) on the TU for each junction
(Supplementary Table 4). We yielded the expected 1458 bp (left)
CapCon_F2
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pHSG396:IS26::TU
CapCon_R1
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Fig. 2 Schematics of the pseudo-compound transposon PTn6762, translocatable unit and positions of primers used in this study. Schematic showing
(a) the characterisation of PTn6762 (HP= hypothetical protein) and the position of the primer pairs to detect (b) the junctions of the PTn6762 in the
chromosome, (c) the presence of the tandem array of TUs in the chromosome and (d) the junctions of the insertion of the TU into pHSG396:IS26.
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Fig. 1 Hyperproduction of TEM-1B in the piperacillin/tazobactam-resistant isolate is mediated by an increase in copy number. a Increase in nitrocefin
hydrolysis by the piperacillin/tazobactam (TZP)-resistant isolate (black line) compared to the TZP-susceptible (pink line) isolate, as measured at an optical
density of 450 nm (OD450), due to hyperproduction of a β-lactamase in the TZP-resistant isolate. All error bars represent the standard error of the mean
(n= 3). b Comparison of the fold change in copy number of the antimicrobial resistance genes present on the pseudo-compound transposon of the TZP-
susceptible isolate (pink circles)/translocatable unit (TU) of the TZP-resistant isolate (black circles) as assessed by qPCR of a single DNA extract
compared to the housekeeping gene uidA. All error bars represent the standard error of the mean (n= 4). Source data are provided as a Source Data file.
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and 1385 bp (right) products (Fig. 2d), consistent with the insertion
of the TU adjacent to IS26 and reforming PTn6762 in pHSG396
(Supplementary Fig. 5B). Subsequent long-read sequencing of the
entire pHSG396:IS26 plasmid following the capture of the TU
established the presence of at least three different plasmid struc-
tures; pHSG396:IS26 without the captured TU (Supplementary
Fig. 6A), pHSG396:IS26 with the captured TU (Supplementary
Figs. 6B and 7) and tandem pHSG396:IS26 with TU (Supplemen-
tary Figs. 6C and 7B). These structures were confirmed by the
presence of sequencing reads which spanned the respective junc-
tions of pHSG396:IS26 and the captured TU. In both plasmid
structures containing the captured TU, at least one captured TU
had the same structure as predicted by the hybrid assembly and was
inserted adjacent to the copy of IS26 cloned into pHSG396,
reforming the pseudo-compound transposon PTn6762. The only
variation was seen in the tandem pHSG396:IS26 plus TU, where
blaOXA-1 was mutated in one of the captured TUs (Supplementary
Fig. 7B). This was due to a single nucleotide insertion resulting in a
frame shift and a terminal stop to the protein.
Replication of excision of the TU. We sought to determine
whether the presence of another mobile IS26 and/or the use of
TZP induced the excision of the TU by replicating the evolu-
tionary event that led to the TZP-susceptible isolate becoming
resistant to TZP in vitro. We found that there was a significant
increase in copy number of all the resistance genes present on
PTn6762, relative to the housekeeping gene uidA, following
exposure to 2 × MIC of TZP (8/4 µg/ml) while there was no
evidence of amplification in the same isolate grown in the absence
of TZP (P value= <0.0001, Fig. 3, Supplementary Table 3). There
was also an increase in copy number when the isolate containing
the pHSG396:IS26 plasmid was exposed to TZP but, again, no
increase in copy number when TZP was absent (P value=
<0.0001, Fig. 3, Supplementary Table 3), therefore TZP can either
select for the maintenance of the excised TU or induce the
excision event, leading to an increase in copy number of the genes
present on PTn6762. In contrast, there was no significant dif-
ference in gene copy number between the TZP-susceptible isolate
with and without the pHSG396:IS26 plasmid grown in the
absence of TZP (P value= 0.1355, Fig. 3, Supplementary Table 3),
underlining that the presence of an extra chromosomal IS26 does
not induce excision of the TU from PTn6762.
Fitness effect of extensive amplification. Hyperproduction of a
protein could result in a fitness cost to the cell due to the
increased metabolic activity. Yet, we found that the amplification
of the TU and carriage of the large plasmid in the TZP-resistant
isolate did not result in a significant change in fitness compared
to the TZP-susceptible isolate in LB broth (LB, P value= 0.6523),
iso-sensitest (ISO, P value= 0.3587) and M9 (P value= 0.5532,
Fig. 4, Supplementary Table 3). We also assessed the relative
fitness of the TZP-susceptible isolate following exposure to TZP
(resulting in the increase in copy number of the resistance genes
present on the TU (Fig. 3)) compared to the TZP-susceptible
grown in the absence of TZP (which did not result in an increase
in copy number (Fig. 3)). Again, we found no significant change
in fitness in LB (P value= 0.1264), ISO (P value= 0.1126) and
M9 (P value= 0.3007, Fig. 4, Supplementary Table 3).
Discussion
Tazobactam is able to inhibit the activity of class A β-lactamases32,
and therefore the presence of blaTEM-1 within the genome of an E.
coli isolate should not result in resistance to TZP. However, two
studies have linked amplification of blaTEM, and therefore hyper-
production of the β-lactamase, with this phenotype17,20, with one
linking amplification and the presence of IS2620. Although, the exact
mechanism of amplification/hyperproduction has remained elusive.
Due to the emergence of a TZP-resistant but 3rd generation
cephalosporins and carbapenems susceptible E. coli and K. pneu-
moniae phenotype12–14, as well as the increasing reliance on TZP as
an empirical treatment6 and the recent interest in the use of TZP as
a carbapenem sparing treatment for extended-spectrum β-lactamase
infections33,34, it is of growing importance to understand the
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transformed with pHSG396 plasmid containing IS26 in the presence of 8/4
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bars represent the standard error of the mean (n= 3). Source data are
provided as a Source Data file.
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Fig. 4 Gene amplification did not incur a fitness cost in the piperacillin/
tazobactam-resistant isolate compared to the piperacillin/tazobactam-
susceptible isolate. Relative fitness of the piperacillin/tazobactam (TZP)-
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(n= 3). Source data are provided as a Source Data file.
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mechanism of amplification. In this study we had the opportunity to
compare a pair of clonal isolates which have evolved within a patient
to become TZP-resistant but remain cephalosporin/carbapenem
susceptible, allowing us to build on recent studies and identify the
mechanism of IS26-mediated amplification of blaTEM-1B which leads
to TZP-resistance.
We found multiple antibiotic resistance genes, including
blaTEM-1B, co-located on a IS26-flanked pseudo-compound trans-
poson PTn6762 on both the TZP-resistant and TZP-susceptible
isolate. The resistance genes tet(D) and blaTEM-1B were both present
on PTn6762 as a result of the insertion of several transposons into
the same location, demonstrated by the presence of multiple
insertion sequences and transposable elements on PTn6762. While
tazobactam has intermediate inhibitory activity towards OXA-116,
we found that the presence of this β-lactamase in the TZP-
susceptible isolate did not confer resistance to TZP, amplification of
blaOXA-1 was involved not in resistance to TZP and TEM-1B is
likely the most important determinant of TZP resistance. Although
we were able to determine that efflux pumps did not have a role in
TZP-resistance in this isolate, we did not investigate whether other
mechanisms, such as change in permeability due to porins, con-
tributed to TZP-resistance. Amplification of blaTEM-1B is achieved
when PTn6762 is excised from the chromosome forming a TU
(Fig. 5), evidenced by the hybrid assembly of the TZP-resistant
isolate, increase in copy number of the antibiotic resistance genes
present on PTn6762 and the capture of the TU in pHSG396:IS26.
While it is a possibility that the presence of the circularised TU in
the hybrid assembly is due to an artefact of the assembly, we
confirmed the presence of the excised TU following capture in
pHSG396:IS26. The TU then re-inserts into the chromosome
adjacent to a copy of IS26 to create a tandem array of TUs,
increasing the copy number of the antibiotic resistance genes pre-
sent on the TU (Fig. 5). While precise excision and formation of a
TU containing the antibiotic resistance gene aphA1a from a
Tn4352B transposon present in a plasmid has been demonstrated
before as a mechanism of movement of antibiotic resistance
gene23,24,35, we have shown that this mechanism can directly result
in gene amplification leading to antibiotic resistance. We found no
evidence from the whole-genome sequencing of the TZP-resistant
isolate of insertion of the TU anywhere else in the chromosome,
except for a gap in sequencing where PTn6762 was originally
situated in the TZP-susceptible isolate adjacent to an IS26. Through
PCR of the left and right junctions of the gap in sequencing, we
confirmed that PTn6762 was still present at this location in the
chromosome of the TZP-resistant isolate and therefore existed as
PTn6762 with tandem repeats of the TU in the chromosome, which
the hybrid assembly was unable to resolve. Rodriguez-Villodres
et al.36 replicated the amplification event leading to TZP-resistance
in E. coli isolates containing blaTEM through exposure to increasing
concentrations of TZP36. They found an increased copy number of
blaTEM in TZP-resistant isolates and regions of amplification, in
which one of the amplified regions contained IS2636. Using the
CHL-resistant pUC vector, pHSG396, containing a copy of IS26
from the TZP-susceptible chromosome, we were also able to
replicate the evolutionary event and capture the excised TU adja-
cent to the IS26 copy in the plasmid, providing evidence of the
insertion event, but we found no evidence of tandem repeats of the
TU in the pHSG396:IS26 plasmid. Therefore, the TU preferentially
re-inserts into the chromosome adjacent to the chromosomally
located IS26 via a conservative Tnp26-dependent but RecA-
independent mechanism, Tnp26 replicative transposition or
RecA-dependent homologous recombination24 producing tandem
repeats of the TU. Again, while this mechanism has previously been
demonstrated in terms of movement of antibiotic resistance
genes23,24, we have shown that this mechanism will cause gene
amplification resulting in antibiotic resistance in a clinical isolate.
This mechanism is of concern as IS26 has been associated with the
transfer of blaNDM-1, in a recent nosocomial outbreak in Ger-
many35, and other carbapenemases37 and therefore represents a risk
of clinical resistance to any carbapenemase inhibitor currently in
development38 which needs to be investigated further. The method
of capture of the TU used in this study can be used to investigate
whether the same mechanism will result in gene amplification and
subsequent reduction in efficacy to other β-lactam/β-lactamase
inhibitors, as well as to further confirm the role of TZP in the
induction of excision of the TU, and therefore gene amplification.
Abdelraouf et al.15 identified five TZP-resistant but 3rd generation
cephalosporin susceptible K. pneumoniae which did not contain
blaTEM, but instead, the most common type of β-lactamase was
SHV-115. These isolates showed a different phenotypic resistance
profile to the E. coli isolates containing blaTEM assessed in the same
study; exhibiting higher MICs against the 3rd generation cepha-
losporins tested and susceptibility to TZP was not restored with
increasing concentrations of tazobactam, potentially indicating a
different mechanism of resistance15. Further work should be
undertaken with both E. coli and K. pneumoniae to fully understand
both the resistance profile and the different mechanisms of resis-
tance involved in this phenotype to aid diagnostics.
Hansen et al.20 associated amplification of blaTEM-1 in an E. coli
clinical isolate with a significant fitness cost20; Fitness of this
isolate was compared to other unrelated clinical isolates of E. coli
which hyperproduced TEM-1 due to promoter mutations, rather
than the same isolate with and without amplification. This
approach can lead to over- or under-estimation of fitness cost, as
genetic background of the isolate can have an impact on the
overall fitness affect, as can the environment fitness is assessed
in39,40. Adler et al.22, however, identified a fitness cost associated
with IS26-mediated amplification of an antibiotic resistance cas-
sette from a plasmid in all lineages tested22. In this study, we were
able to compare the fitness of the paired clinical isolates and
in vitro evolved isolates with and without amplification of the TU
and found that there was no significant difference in fitness cost,
despite amplification of a >10 kb region with multiple function-
ally transcribed genes and, in terms of the TZP-resistant clinical
PTn6762
Chromosome IS26IS26 Chromosome
TU
1
2
3
4
5
Fig. 5 Proposed mechanism of hyperproduction of TEM-1B mediated by
IS26. Schematic of the proposed mechanism of amplification leading to
hyperproduction of TEM-1B; (1) a pseudo compound transposon, PTn6762,
is present on the chromosome flanked by two copies of IS26. (2) PTn6762
is excised from the chromosome, (3) which then forms a TU which (4) re-
inserts into the chromosome adjacent to the chromosomally located IS26
(5) creating a tandem array of the TU and increasing the copy number of
blaTEM-1B.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18668-2
6 NATURE COMMUNICATIONS |         (2020) 11:4915 | https://doi.org/10.1038/s41467-020-18668-2 | www.nature.com/naturecommunications
isolate, has acquired a large plasmid. If this lack of fitness cost is
translated into a physiological environment, it may result in the
TZP-resistant phenotype persisting. While there was no observed
fitness effect of amplification on the single isolate in this study,
the effect of amplification on bacterial fitness needs to be exten-
sively investigated as it may not be a global phenomenon
Resistance to the β-lactam/β-lactamase inhibitor TZP can be
the result of gene amplification, and subsequent hyperproduction,
of blaTEM-1B. The mechanisms involved in this gene amplification
are the IS26-associated excision and re-insertion into the chro-
mosome, of a TU containing blaTEM-1B derived from a chromo-
somally located pseudo-compound transposon PTn6762, which is
either selected by or in response to exposure to TZP. The TU is
capable of re-inserting into the chromosome, creating a tandem
array of TUs and increasing the copy number of blaTEM-1B. In this
clinical isolate and an in vitro evolved isolate, we found that there
was no effect on fitness due to the amplification and subsequent
carriage of high numbers of the TU. This mechanism of ampli-
fication, and the subsequent hyperproduction, of blaTEM-1B is an
important consideration if treatment failure involving TZP
occurs, as well as other β-lactam/β-lactamase inhibitor combi-
nations, and when using genomic data to predict resistance/sus-
ceptibility to β-lactam/β-lactamase inhibitor combinations.
Methods
Ethics statement. All E. coli isolates used in this study were collected at the RLUH
(Liverpool, UK) as part of routine clinical diagnostics procedures. The bacterial
isolates were identified in the hospital biobank database as having interesting
resistance profiles by the Consultant Microbiologist. Isolates were retrieved from the
Microbiology Laboratory by Thomas Edwards (Liverpool School of Tropical
Medicine), who has an NHS research passport enabling work in the hospital
laboratories. Antimicrobial susceptibility data and the treatment data were anon-
ymised, unlinked to patient identifiers and data produced in this study was not used
for the treatment or management of patients, therefore requirement for ethical
approval and informed patient consent was not required. This was confirmed using
the online NHS Research Ethics Committee review tool http://www.hra-
decisiontools.org.uk/ethics/.
Bacterial isolates, media and antibiotics. Clinical isolates of E. coli isolated from
blood cultures between 2010 and 2017 at the RLUH (Liverpool, UK) which were
found to be carbapenem and cephalosporin susceptible but TZP resistant using the
disk diffusion method of antimicrobial susceptibility testing (AST) were initially
identified from isolate records. Isolate records were then searched for a corre-
sponding carbapenem, cephalosporin and TZP susceptible isolates, isolated in the
same or a previous infection episode from the same patient. Using these criteria, we
identified five paired clinical isolates of E. coli. All isolates had been stored at the
time of blood culture isolation in glycerol broth at −80 °C.
All isolates were grown on LB (Lennox) agar at 37 °C for 18 h followed by
growth in LB, (Sigma, UK), ISO (Oxoid, UK) or M9 (50% (v/v) M9 minimal salts
(2x) (Gibco, ThermoFisher Scientific, USA), 0.4% D-glucose, 4 mM magnesium
sulphate (both Sigma, UK) and 0.05 mM calcium chloride (Millipore, USA)) at
37 °C for 18 h at 200 rpm.
Piperacillin, tazobactam (both Cayman Chemical, USA), gentamicin (GEN),
and amoxicillin trihydrate:potassium clavulanate (4:1, AMC) was solubilised in
molecular grade water (all Sigma, UK), while CHL and tetracycline (TET) (both
Sigma, UK) were solubilised in ethanol (VWR, USA) and ciprofloxacin (CIP) was
solubilised in 0.1 N hydrochloric acid solution (both Sigma, UK). All stock
solutions of antibiotics were filter sterilised through a 0.22 µm polyethersulfone
filter unit (Millipore, USA). In all assays, unless stated, tazobactam was used at a
consistent concentration of 4 µg/ml and the piperacillin concentration was altered.
Restriction enzyme digestion. RFLP analysis of 1 µg of 16S rRNA PCR amplicon
from the 10 putative clonal isolates were digested with AlwNI, PpuHI and MslI
(all New England Biolabs (NEB), USA) and 1 µg of long fragment genomic DNA
extracts of 153964, 152025, 190693 and 169757 were digested with SpeI and MslI
(both NEB, USA) for 1 h at 37 °C. Both RFLP digest reactions were incubated for
5 min at 80 °C and immediately run on a 1% agarose gel. Enzyme digest of 500 ng
of plasmid DNA extracted from 190693 and 169757 was performed with PpuMI
and XhoI (both NEB, USA) and immediately run on a 1% agarose gel following
incubation for 1 h at 37 °C. RFLP was performed on a single DNA extract from
each bacterial isolate.
Antimicrobial susceptibility testing. Initial AST for cefpodoxime (CPD), cefox-
itin (FOX), TZP, meropenem (MEM), CIP, cefotetan (CTT), amikacin (AMK),
ertapenem (ETP), AMC, CHL and ampicillin (AMP) was performed in RLUH
clinical laboratory using the disk diffusion method, according to either British
Society for Antimicrobial Chemotherapy (BSAC) or EUCAST guidelines for
Antimicrobial Susceptibility Testing41–43.
MIC for TZP, GEN, CIP, CHL, AMC and TET were performed using the broth
microdilution method, in cation adjusted Mueller Hinton Broth (CA-MHB, Sigma,
UK), following EUCAST Guidelines44. Efflux pump inhibition was performed using
PAβN as a supplement in CA-MHB at a final concentration of 50 µM, inhibition of
TEM-1B was determined with piperacillin with increasing concentrations of
tazobactam (4, 8 and 16 µg/ml) and inhibition of OXA-1 was determined with TZP
plus 100mM sodium chloride (Sigma, UK). Each MIC was performed in triplicate
using independent bacterial cultures, each with three technical replicates.
Nitrocefin assay. β-lactam hydrolysis was evaluated using a colorimetric nitrocefin
assay. Cell lysates were obtained from triplicate cultures of 190693 and 169757 in
LB, adjusted to an optical density at 600 nm (OD600) of 0.1. Cultures (10 ml) were
centrifuged at 14,000 × g for 5 min, the supernatant discarded, and the pellet
resuspended in 5 ml phosphate-buffered saline (PBS). The cultures were sonicated
for three intervals of ten seconds, on ice, using a Soniprep 150 plus (MSE cen-
trifuges, UK). The lysed cultures were centrifuged at 14,000 × g for 5 min, and the
supernatant taken as the culture lysate.
A total of 90 µl of this lysate was then added to 10 µl of 0.5 mg/ml nitrocefin
solution (Sigma, UK) in a 96-well microplate, in triplicate. The absorbance of the
plate was read at an optical density of 450 nm (OD450) every 20 s for 25 min, using
a SPECTROstar OMEGA spectrophotometer (BMG lab systems, Germany). This
assay was performed in triplicate using independent bacterial cultures.
Whole-genome sequencing and bioinformatics. Whole-genome sequencing was
performed from a single DNA extract for each isolate. Illumina MiSeq 2 × 250 bp
short-read sequencing of long fragment DNA extractions from isolates 190693 and
169757, as well as adapter trimming of the sequencing reads, were provided by
MicrobesNG (MicrobesNG, UK).
The same long fragment DNA extracts were processed using the SQK-LSK109
ligation and SQK-RBK103 barcoding kit and sequenced on an R9.4.1 flow cell with
an ONT MinION. Sequencing reads were basecalled during the sequencing run
using MinKNOW (v19.05.0), de-multiplexing and adapter trimming of the
basecalled reads were performed using Porechop (v0.2.4) and finally sequencing
reads were filtered for a quality score of 10 via Filtlong (v0.2.0).
Both Illumina short-read and ONT long-read sequences were assembled using
Unicycler (v0.4.745), with the quality of the assembly assessed using QUAST
(v5.0.246), annotated using Prokka (v1.14.047) and visualised using Bandage (v0.8.148).
Sequence type and serotype of both 190693 and 169757 were determined using
Multi-Locus Sequence Typing (MLST, v2.0.449) and SerotypeFinder (v2.0.150),
respectively. The relatedness of the two genomes were compared using MUMmer
(v3.2351) and the ANI was calculated using OrthoANI (v0.93.152). Presence of
acquired antimicrobial resistance genes within the two genomes were assessed
using ResFinder with minimum threshold of 90% and a minimum length of 60%
(v3.253) and segments of the two genomes were characterised using SnapGene®
software (v3.3.4, from GSL Biotech; available at snapgene.com). Finally, plasmid
replicons were identified using PlasmidFinder (v2.0.1)54.
Long-read sequencing reads of 190693 and 169757 were mapped to a predicted
structure of three TUs in tandem using BWA MEM55 (https://github.com/lh3/bwa,
v0.7.17-r1188). Aligned sequencing reads were converted to FASTQ using samtools
(ref. 56 v1.10) and then used to a build a consensus sequence with Medaka (https://
github.com/nanoporetech/medaka, v0.11.5) and compared to the predicted tandem
TU structures in EasyFig (ref. 57 v2.2.2).
Competent cell preparation. The TZP-susceptible isolate was made competent
according to Chung et al.58.
Quantitative PCR. Changes in gene copy number of blaTEM-1B, blaOXA-1, aac(3)-
lla, aac(6’)-lb-cr, tet(D) were calculated via qPCR, using the ΔΔCT method for
relative quantitation of these genes against the single copy uidA housekeeping gene.
Each qPCR reaction contained 6.25 µl QuantiTect® SYBR Green PCR buffer
(Qiagen, UK), 0.4 µM forward and reverse primers (Supplementary Table 4), 1 ng
of extracted DNA, and molecular grade water to a final volume of 12.5 µl. Reactions
were processed using a Rotor-Gene Q (Qiagen, Germany), using the following
protocol; an initial denaturation step of 95 °C for 5 min, followed by 40 cycles of;
DNA denaturation at 95 °C for 10 s, primer annealing at 58 °C for 30 s, and primer
extension at 72 °C for 10 s with fluorescence monitored in the FAM channel. High
resolution melt analysis was carried out over a temperature range of 75 °C to 90 °C,
increased in 0.1 °C increments, in order to confirm specific amplification.
Fluorescence thresholds were set manually for calling Ct values, at 5% of the
difference between baseline and maximum fluorescence.
The mean qPCR Ct value for the uidA gene from each strain was taken using at
least three replicates qPCR reactions, and the ΔΔCT method was utilised to
determine to fold change using at least triplicate qPCR reactions for each AMR
gene from a single DNA extract of each isolate.
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In vitro evolution of susceptible isolate. The clinical isolate 190693 (TZP-sus-
ceptible isolate) and 190693 transformed with pHSG396:IS26 were subcultured into
10 ml LB and 10 ml LB plus 35 µg/ml CHL, respectively, and incubated at 37 °C for
18 h at 200 rpm. Following incubation 10 µl of 190693 was subcultured into 10 ml
LB and 10 ml LB plus 8/4 µg/ml TZP and 10 µl of 190693 with pHSG396:IS26 was
subcultured into 10 ml LB plus 35 µg/ml CHL and 10 ml LB plus 35 µg/ml CHL
and 8/4 µg/ml TZP and incubated at 37 °C for 24 h at 200 rpm. Each evolution
experiment was performed in triplicate using independent cultures. Genomic DNA
from each of the four cultures from each replicate were extracted for qPCR fol-
lowing the protocol described in Supplementary Methods 1, except a single
replicate of each of the three biological replicates were performed.
TU capture. The TZP-susceptible isolate 190693 transformed with pHSG396:IS26
was grown in the presence of TZP and CHL as previously stated. Following
selection, the culture was serially diluted 1/10 in PBS down to 10−7 dilution and
50 µl of each dilution was plated out on to LB agar supplemented with 35 µg/ml
CHL and 16/4 µg/ml TZP. Five single colonies were selected and subcultured into
10ml LB plus 35 µg/ml CHL and 16/4 µg/ml TZP for 18 h at 37 °C and 200 rpm and
the plasmid extracted following the protocol in Supplementary Methods 1. The
purified plasmids were transformed into NEB® 5-alpha competent E. coli (NEB, US)
following the protocol in Supplementary Methods 1 and plated out on to LB agar
supplemented with 35 µg/ml CHL and 16/4 µg/ml TZP and incubated at 37 °C for
18 h. A single colony from each transformation was subcultured into 10 ml LB
supplemented with 35 µg/ml CHL and 16/4 µg/ml TZP and incubated at 37 °C,
200 rpm for 18 h and the plasmid extracted following the protocol in Supplementary
Methods 1. The initial pHSG396:IS26 plasmid extract and pHSG396: IS26 plasmid
selected in TZP and extracted from NEB® 5-alpha E. coli were digested with XhoI
(NEB, US) and EcoRI for 1 h at 37 °C, followed by a 20min incubation at 65 °C and
run on a 1% agarose gel. A single DNA extract of pHSG396:IS26 selected in TZP
was sequenced on a MinION, adapters removed, and sequencing reads filtered as
stated above, except using a quality score of 50. Long-read sequencing reads of the
captured TU in pHSG396:IS26 were mapped to three predicted plasmid structures,
pHSG396:IS26, pHSG396:IS26 plus TU and tandem pHSG396:IS26 plus TU and
used to build a consensus sequence using the method described above.
Comparative fitness. The relative fitness of 169757 (TZP-resistant) and 190693
(TZP-susceptible) grown in the presence of 8/4 µg/ml TZP, compared to 190693
and 190693 grown in the absence of TZP, respectively, were assessed comparatively
in LB, ISO and M9. Each culture was diluted to an OD600 of 0.1 in the respective
media, then further diluted 1/1000 in the same media and 150 µl of each diluted
culture added to a flat bottom, 96-well microtitre plate in duplicate as well as 150 µl
of the media as a negative control. The 96-well plate was incubated at 37 °C and the
OD600 of each well was measured with 100 flashes every 10 min over 24 h, with
orbital shaking at 200 rpm between readings, using a Clariostar Plus microplate
reader (BMG Labtech, Germany). The relative fitness compared to either 190693 or
190693 grown in the absence of TZP between absorbance values 0.02 and 0.08 and
a minimum R value of 0.9905 was estimated using BAT version 2.159. Comparative
fitness was performed in triplicate with independent bacterial cultures, with two
technical replicates for each replicate.
Statistical analysis. Statistical analysis of comparison for the qPCR assay of the
antibiotic resistance genes was performed using the two-way ANOVA with
Uncorrected Fisher LSD test. Statistical analysis of the nitrocefin assay was per-
formed using the two-way ANOVA test. Statistical analysis of relative fitness of
169757 and 190693 grown in the presence of TZP was performed using ordinary
one-way ANOVA with Uncorrected Fisher LSD test. All statistical tests were
performed using GraphPad Prism version 8.2.1. Means and standard error of the
mean of all data presented in this study are available in Supplementary Table 3.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All sequencing reads and assemblies were deposited to GenBank under the BioProject
number PRJNA607545. Consensus sequences of pHSG396:IS26, pHSG396:IS26 plus
translocatable unit (TU) and tandem pHSG396:IS26 plus TU are available in
Supplementary Fig. 6A–C. Source data are provided with this paper.
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